-
Home
-
Product
-
IMMUNOHISTOCHEMISTRY
-
INSTRUMENT
-
MOLECULAR
-
HISTOLOGY
-
CYTOLOGY
-
DIGITAL PATHOLOGY
-
-
Solution
-
Support
-
About
-
Contact
2025 114th Annual Meeting of the Japanese Society of Pathology
2025-04-03April 17-19
Celnovte Biotechnology Booth Number
Booth B-34
About the Japanese Society of Pathology
The 114th Annual Meeting of the Japanese Society of Pathology (JSP) in 2025 will take place grandly from April 17 to 19 at the Sendai International Conference Center in Japan. Founded in 1911, the Japanese Society of Pathology (JSP) is one of the most authoritative and influential academic organizations in pathology in Japan. The society brings together leading pathologists dedicated to researching the fundamental mechanisms of diseases, developing precise diagnostic technologies, and advancing translational medicine studies. It also attracts numerous outstanding technical experts who provide high-quality techniques and professional expertise in the field of pathology.
The JSP Annual Meeting is one of the largest and most prestigious academic events in Japan’s pathology community. It promotes the development and application of pathological scientific research through academic exchanges, sharing of research findings, and technology exhibitions. The theme of this year’s meeting is “Opening New Doors in Pathology,” focusing on cutting-edge breakthroughs and innovations in the field. It explores new directions and opportunities for pathology in disease diagnosis, treatment, and prevention.
Celnovte Biotechnology Booth Number B-34. We look forward to meeting you there!
Booth Information
Event Highlights
- CNT620 Fully Automated HE High-Definition Staining and Coverslipping All-in-One Machine
- CNT520 Fully Automated Special Staining and Coverslipping All-in-One Machine
- CNT480 Fully Automated Liquid-Based Cytology Immunochemical Staining Instrument
- CNT320RX Fully Automated Immunohistochemistry Staining Machine
- CNT160 Digital Pathology Scanner
- Complete Solution for Frozen Section Immunohistochemistry
- Globally Leading Mouse-Rabbit Synchronous Amplification Secondary Antibody Detection System
- Super-ISH Molecular Diagnostic Precision Solution
About Celnovte Biotechnology
Celnovte Biotechnology Co., Ltd. (Celnovte) was established in 2010, with its headquarters located in Zhengzhou, China. The company focuses on the development and production of reagents and instruments. It has an instrument R&D subsidiary in Shenzhen, a scientific product development division in Suzhou, and a reagent R&D facility in Maryland, USA. Its facilities in China comply with NMPA & GMP standards and have passed ISO13485, ISO9001, and CE certifications. Today, Celnovte has built an extensive domestic and international pathology network, serving numerous top-tier hospitals in China and over 10 countries worldwide.
Celnovte Biotechnology specializes in the R&D, production, and sales of pathology diagnostic reagents and instruments. It has prioritized launching internationally leading immunohistochemistry and in situ hybridization products. Among them, the Micro-stacker secondary antibody detection system offers exceptional sensitivity and specificity. The Polystacker technology drastically shortens intraoperative frozen immunohistochemistry experiments to 10 minutes. Additionally, the cutting-edge Super-ISH mRNA in situ hybridization technology enables precise detection of target RNA at single-molecule and single-cell levels.
Celnovte Biotechnology boasts a comprehensive platform of pathology diagnostic equipment, including fully automated staining and coverslipping all-in-one machines, fully automated special staining and coverslipping all-in-one machines, special staining machines, fully automated liquid-based cytology immunochemical staining instruments, high-throughput immunohistochemistry staining machines, and digital scanners. Since their launch in 2018, over 600 fully automated immunohistochemistry staining machines have been successfully installed globally. Celnovte is a high-tech enterprise rooted in innovation, committed to advancing precision medicine in pathology diagnostics.
